As of 2025-07-06, the Intrinsic Value of NeuroScientific Biopharmaceuticals Ltd (NSB.AX) is 0.08 AUD. This NSB.AX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 0.14 AUD, the upside of NeuroScientific Biopharmaceuticals Ltd is -40.00%.
The range of the Intrinsic Value is 0.07 - 0.14 AUD
Based on its market price of 0.14 AUD and our intrinsic valuation, NeuroScientific Biopharmaceuticals Ltd (NSB.AX) is overvalued by 40.00%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 0.07 - 0.14 | 0.08 | -40.0% |
| DCF (Growth 10y) | 0.09 - 0.24 | 0.11 | -19.7% |
| DCF (EBITDA 5y) | 0.10 - 0.12 | 0.11 | -23.5% |
| DCF (EBITDA 10y) | 0.10 - 0.13 | 0.11 | -20.1% |
| Fair Value | 0.08 - 0.08 | 0.08 | -44.55% |
| P/E | 0.08 - 0.18 | 0.13 | -5.8% |
| EV/EBITDA | 0.12 - 0.18 | 0.15 | 5.7% |
| EPV | (0.29) - (0.68) | (0.49) | -447.4% |
| DDM - Stable | 0.08 - 0.60 | 0.34 | 140.5% |
| DDM - Multi | 0.02 - 0.11 | 0.03 | -80.3% |
| Market Cap (mil) | 10.70 |
| Beta | 0.42 |
| Outstanding shares (mil) | 76.43 |
| Enterprise Value (mil) | 6.21 |
| Market risk premium | 5.10% |
| Cost of Equity | 10.25% |
| Cost of Debt | 5.00% |
| WACC | 6.87% |